...we subsequently identified two patients with glioblastoma (GBM; WHO grade 4) with BRAF V600E mutations in their tumors...a 66-year-old man was also given concurrent cediranib, a pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in a clinical trial. Neither patient harbored IDH1 mutation in the tumor, and both are currently alive and free of progression at 19 and 36 months, respectively.